<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873168</url>
  </required_header>
  <id_info>
    <org_study_id>ETC 2018-001</org_study_id>
    <nct_id>NCT03873168</nct_id>
  </id_info>
  <brief_title>Post-Market Evaluation of HEMOBLAST™ Bellows in Open Gynecological, Urological, ENT, Head, Neck, and Vascular Surgeries</brief_title>
  <acronym>NOBLE-Open</acronym>
  <official_title>Post-Market Evaluation of HEMOBLAST™ Bellows Performance and Safety in Open Gynecological, Urological, ENT, Head and Neck, and Vascular Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biom'Up France SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biom'Up France SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, multi-national single arm study to evaluate the performance and&#xD;
      safety of HEMOBLAST™ Bellows in open gynecological, urological, ENT and head and neck, and&#xD;
      vascular surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multi-center, multi-national single arm study conducted in Austria, France,&#xD;
      and Germany to evaluate the performance and safety of HEMOBLAST™ Bellows in open&#xD;
      gynecological, urological, ENT, head and neck, and vascular surgery. Up to 120 subjects will&#xD;
      be enrolled at up to 10 sites, with a minimum of 8 subjects enrolled in each surgical&#xD;
      specialty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Indication withdrawn&#xD;
  </why_stopped>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Hemostasis</measure>
    <time_frame>Intraoperatively, expected within 3-10 minutes of application</time_frame>
    <description>The proportion of subjects for which hemostasis was achieved after application of HEMOBLAST™ Bellows.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-bleeding at Target Bleeding Site</measure>
    <time_frame>Intraoperative, prior to surgical closure of the subject</time_frame>
    <description>The rate of target bleeding site re-bleeding after hemostasis has been achieved with HEMOBLAST™ Bellows</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-operation due to bleeding</measure>
    <time_frame>Post-operatively, expected within 1-30 days of the surgical procedure</time_frame>
    <description>The rate of re-operation due to post-operative bleeding/hemorrhage after treatment with HEMOBLAST™ Bellows</description>
  </secondary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Hemostasis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HEMOBLAST™ Bellows</intervention_name>
    <description>Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing open gynecological, urological, ENT and head and neck, and vascular&#xD;
        procedures that meet all of the inclusion criteria and none of the exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Pre-operative Inclusion Criteria:&#xD;
&#xD;
          -  Patient is undergoing a non-emergent open gynecological, urological, ENT, head and&#xD;
             neck, or vascular surgery&#xD;
&#xD;
          -  Patient is willing and able to give prior written informed consent for investigation&#xD;
             participation;&#xD;
&#xD;
          -  Patient is 18 years of age or older.&#xD;
&#xD;
        Intra-operative Inclusion Criteria&#xD;
&#xD;
          -  Patient has one or more target bleeding sites (TBS) for which control of bleeding by&#xD;
             conventional procedures is ineffective or impractical.&#xD;
&#xD;
          -  The TBS(s) has been treated with HEMOBLASTTM Bellows as per their instructions for&#xD;
             use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant, planning on becoming pregnant during the follow-up period, or&#xD;
             actively breast-feeding;&#xD;
&#xD;
          -  Patient has a known sensitivity or allergy to bovine and/or porcine substance(s) or&#xD;
             any other component(s) of the hemostatic agent;&#xD;
&#xD;
          -  Patient has religious or other objections to porcine, bovine, or human components;&#xD;
&#xD;
          -  Patient has any significant coagulation disorder;&#xD;
&#xD;
          -  Patient has any other contraindications, warnings, precautions of the Approved&#xD;
             Instruction For Use of HEMOBLAST™ Bellows preventing his/ her inclusion&#xD;
&#xD;
          -  Patient is not appropriate for inclusion in the clinical trial, per the medical&#xD;
             opinion of the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Vilz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unversity Hospital Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniklinikum</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Rive Gauche</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Koln, Krankenhaus Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Franzikus-Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

